Tempus introduces prostate digital pathology algorithm
Tempus AI has launched the ArteraAI Prostate Test (mHSPC), a CLIA-certified, CAP-accredited digital pathology tool designed to personalize therapy for metastatic hormone-sensitive prostate cancer patients, addressing a key treatment gap.
Tempus AI announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform personalization of therapy intensity in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient’s clinical information and histopathology biopsy image to produce a personalized risk estimate of the patient’s likelihood of prostate cancer-specific mortality. This algorithmic insight addresses a significant gap in the treatment landscape for the approximately 25,000 patients newly diagnosed with metastatic prostate cancer in the U.S. each year.
Clinicians will be able to order the ArteraAI Prostate Test (mHSPC) as an add-on to Tempus’ solid tumor portfolio across all ordering modalities.
